499 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Purchased by Gemmer Asset Management LLC

Gemmer Asset Management LLC purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 499 shares of the medical equipment provider’s stock, valued at approximately $222,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Creekmur Asset Management LLC increased its stake in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. Delos Wealth Advisors LLC boosted its holdings in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares during the period. LRI Investments LLC acquired a new stake in shares of Intuitive Surgical in the first quarter valued at about $30,000. Baystate Wealth Management LLC boosted its holdings in Intuitive Surgical by 150.0% in the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the period. Finally, MCF Advisors LLC grew its holdings in shares of Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded up $3.70 during mid-day trading on Tuesday, reaching $469.23. The company’s stock had a trading volume of 884,791 shares, compared to its average volume of 1,561,007. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $470.49. The company has a market capitalization of $166.44 billion, a P/E ratio of 84.43, a PEG ratio of 4.97 and a beta of 1.39. The firm’s fifty day moving average price is $438.40 and its two-hundred day moving average price is $405.13.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company posted $1.18 EPS. The business’s quarterly revenue was up 14.5% on a year-over-year basis. On average, research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 175 shares of the stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $387.22, for a total transaction of $67,763.50. Following the completion of the sale, the senior vice president now directly owns 533 shares in the company, valued at approximately $206,388.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Robert Desantis sold 240 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $464.76, for a total value of $111,542.40. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,558,968.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $387.22, for a total value of $67,763.50. Following the transaction, the senior vice president now owns 533 shares in the company, valued at approximately $206,388.26. The disclosure for this sale can be found here. Insiders have sold a total of 15,547 shares of company stock worth $6,735,194 in the last 90 days. 0.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of recent analyst reports. Barclays boosted their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Piper Sandler increased their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price objective for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Finally, Citigroup upped their target price on shares of Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $442.30.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.